和誉-B(02256)：和誉医药CSF-1R抑制剂贝捷迈®获中国NMPA批准

Core Viewpoint - The approval of Beijiemai® (Pimitespib Hydrochloride Capsules) by the NMPA for the treatment of symptomatic tenosynovial giant cell tumors (TGCT) in adult patients marks a significant advancement for the company and provides a new treatment option for patients in China [1] Company Summary - The company's subsidiary, Shanghai Heyu Biopharmaceutical Technology Co., Ltd. ("Heyu Pharma"), announced the approval on December 22, 2025 [1] - Following the approval, Merck will expedite the availability of this product to TGCT patients in China [1]